bluebird bio Stock (NASDAQ:BLUE)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.47

52W Range

$0.45 - $5.53

50D Avg

$0.53

200D Avg

$0.95

Market Cap

$89.78M

Avg Vol (3M)

$7.38M

Beta

0.80

Div Yield

-

BLUE Company Profile


bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

375

IPO Date

Jun 19, 2013

Website

BLUE Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Other Revenue$858.00K$812.00K-
Product$2.74M$2.85M-
Royalty And Other Revenue--$21.08M
Service--$114.06M

Fiscal year ends in Dec 22 | Currency in USD

BLUE Financial Summary


Dec 22Dec 21Dec 20
Revenue$3.60M$3.66M$250.73M
Operating Income$-287.09M$-590.91M$-629.51M
Net Income$-266.58M$-562.64M$-618.70M
EBITDA$-277.21M$-539.31M$-635.98M
Basic EPS$-3.39$-8.16$-9.95
Diluted EPS$-3.39$-8.16$-9.95

Fiscal year ends in Dec 22 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 14, 24 | 11:14 AM
Q1 24May 11, 24 | 5:50 PM
Q4 23Mar 26, 24 | 2:52 PM

Peer Comparison


TickerCompany
YMABY-mAbs Therapeutics, Inc.
PTCTPTC Therapeutics, Inc.
ZNTLZentalis Pharmaceuticals, Inc.
CVACCureVac N.V.
SRPTSarepta Therapeutics, Inc.
TVTXTravere Therapeutics, Inc.
KPTIKaryopharm Therapeutics Inc.
VIRVir Biotechnology, Inc.
VKTXViking Therapeutics, Inc.
AGIOAgios Pharmaceuticals, Inc.
KRYSKrystal Biotech, Inc.
MRSNMersana Therapeutics, Inc.
HEPAHepion Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.